Development of a Simple, Sensitive and Rapid Quantitative Analytical Method for Lomefloxacin by High Performance Liquid Chromatography
An attempt has been made to develop a simple, sensitive and rapid high performance liquid chromatographic (HPLC) method of analysis for lomefloxacin as in pharmaceutical dosage form using 0.025 M phosphoric acid and acetonitrile (80:20) as mobile phases. The mobile phase was used as solvents to dissolve lomefloxacin and 0.0122 mg/mL stock solution was prepared. Lomefloxacin solution was scanned with UV-spectrophotometer and the absorption maximum (λmax) was found to be 287 nm. This method was successfully applied to five eye drop dosage forms of lomefloxacin encoded as pp1, pp2, pp3, pp4 and pp5 marketed by five different pharmaceutical companies and the result was found to be satisfactory and reproducible. The method was validated by spiked recovery experiments and shown to be linear for lomefloxacin. The method can be used for routine analysis in both research laboratories, and pharmaceutical and chemical industries to analyze the drugs and chemicals without any interference by the excipients.
Key words: Lomefloxacin; HPLC; Analysis; Reproducible.
SJPS 2011; 4(1): 69-73
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.